The Responsiveness of Patients’ Quality of Life to Dental Caries Treatment—A Prospective Study

<div><p>The objective of this study was to determine the responsiveness of oral health–related quality of life (OHRQoL) (oral health impact profile [OHIP] and oral impact on daily performance [OIDP]) and health-related quality of life (HRQoL) (World Health Organization quality of life scale, brief [WHOQOL-BREF]) in dental caries restoration treatment. The study also aimed to assess the influence of treatment on the responsiveness of patients’ quality of life (QoL). A total of 126 patients (aged 16–40 years) received dental caries restoration treatment with a 2-week follow-up and pre- and posttreatment interviews by questionnaire. Patients were assessed for their perceptions of OHRQoL and HRQoL by using the OHIP, OIDP, and WHOQOL-BREF measures. The responsiveness of all outcome measurements was assessed by effect size (ES). Stepwise multiple regression analysis was used to examine the association with the responsiveness of all outcome measurements. Significant differences were found between OIDP (ES = 0.39), OHIP (ES = 0.54), and WHOQOL-BREF (ES = 0.13) with regard to pretreatment and posttreatment (p-values: <0.0001, <0.0001, and 0.0120, respectively). Sex and dental caries status at baseline were significantly associated with responsiveness by all measurements. This study suggests that dental caries treatment moderately improves OHRQoL, but is less related to HRQoL. Furthermore, the number of dental caries and restoration are important factors affecting the improvement of patients’ perceived OHRQoL.</p></div

The association with responsiveness of all measurements for patients with dental caries treatment.

<p>The association with responsiveness of all measurements for patients with dental caries treatment.</p

Discriminatory ability of all measurements in perceived oral and general health condition.

<p>Discriminatory ability of all measurements in perceived oral and general health condition.</p

Responsiveness of all measurements assessed in 126 subjects with dental caries treatment.

<p>Responsiveness of all measurements assessed in 126 subjects with dental caries treatment.</p

The distribution of oral examination status, oral health behavior and treatment status (N = 135).

<p>The distribution of oral examination status, oral health behavior and treatment status (N = 135).</p

Disease free survival of bladder cancer.

<p>(A).never use and ever use of pioglitazone. (B).never use, cumulative dose <10500 mg and >10500 mg of pioglitazone. (C).never use, duration of therapy <12 months and >12 months of pioglitazone.</p

Disease free survival of newly developed chronic kidney disease after use of pioglitazone.

<p>(A).never use and ever use of pioglitazone. (B). never use, cumulative dose <10500 mg and >10500 mg of pioglitazone. (C). never use, duration of therapy <12 months and >12 months of pioglitazone.</p

Hazard ratio of bladder cancer.

<p>Adjusted by sex, age, duration of diabetes, other diabetes medications, income (monthly income NT$20,000), residential area, nephritis, chronic kidney disease, kidney infections, hydronephrosis, calculus of the lower urinary tract, cystitis, other disorders of the urethra and urinary tract, hypertension and hyperlipidemia. The adjusted HR of newly developed chronic kidney disease and calculus of the kidney and ureter were computed with the indicated variable of pioglitazone use.</p

Multivariable adjusted hazard ratios of all-cause mortality by various definitions of interruption and non-adherence.

<p>Multivariable adjusted hazard ratios of all-cause mortality by various definitions of interruption and non-adherence.</p

Hazard ratios of newly developed chronic kidney disease.

<p>Adjusted by age, sex, diabetes duration, income (monthly income NT$20,000) residential area, nephritis, chronic kidney disease, kidney infections, hydronephrosis, calculus of the lower urinary tract, calculus of the kidney and ureter, cystitis, other disorders of the urethra and urinary tract, other diabetes medication including sulfonylureas, metformin, acarbose, rosiglitazone and insulin. The adjusted HR of hypertension, hyperlipidemia and other diabetes medication were computed with the indicated variable of pioglitazone use.</p